Canadian per capita use and spending on drugs for chronic retinal diseases among the highest in the OECD
Spending on drug class grew by 16.7% in 2017 and stands at just under $700 million
OTTAWA, Dec. 12, 2018 /CNW/ - The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the latest edition of the Market Intelligence Report: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs for Retinal Conditions, 2017.
Biologic anti-VEGFs are a fast growing class of drugs used to treat age-related macular degeneration (AMD) and other retinal conditions. AMD is the leading cause of visual impairment in adults over 50, with the more serious "wet" form affecting over 100,000 Canadians.
The report, which focuses on Lucentis and Eylea, the two anti-VEGF drugs approved for retinal conditions, also considers Avastin, an anti-VEGF cancer drug that has widespread off-label use for retinal diseases.
This is the second edition of the PMPRB's Market Intelligence Report series, each featuring a therapeutic class of drugs marked by relatively high-use and high-prices in Canada compared to foreign markets.
Quick Facts
In 2017, the combined sales of Lucentis and Eylea in Canada climbed to $692 million, an increase of $100 million or 16.7% over the previous year. Since 2008, cumulative sales for Lucentis and Eylea in Canada have amounted to more than $3.6 billion.
Anti-VEGF drugs are predominantly reimbursed by public drug plans in Canada, as the senior population has a higher prevalence of AMD and other age-related retinal conditions.
The average annual treatment cost for Lucentis is about $8,500 in public and private drug plans, while Eylea is comparable at around $8,300 in public plans and $8,700 in private plans. Avastin costs only a fraction of this at roughly $400.
Canadian list prices of Lucentis and Eylea are the second highest among the PMPRB7, trailing only the US, with median PMPRB7 prices 37% lower for Lucentis and 15% lower for Eylea in 2017.
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...
On May 1, 2024, Toronto Public Health (TPH) will host Diverse Dialogues: Stigma & Breaking Barriers. The event will bring together distinguished speakers to explore the challenging and thought-provoking topic about how negative labels and biases...
As the demand for cosmetic procedures continues to rise, patients are seeking more advanced and effective options for achieving a youthful and rejuvenated appearance. In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face...
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:
Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....